{
    "clinical_study": {
        "@rank": "152875", 
        "arm_group": [
            {
                "arm_group_label": "Fluoxetine + Valsartan", 
                "arm_group_type": "Experimental", 
                "description": "The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.\nAdd-on treatment to 40 mg per day of valsartan"
            }, 
            {
                "arm_group_label": "Fluoxetine + Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.\nAdd-on treatment to placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to identify evidence-based guidelines for treating major\n      depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients.\n      To achieve this goal, the investigators aim to: (1) evaluate the risks and benefits of\n      adjunctive pharmacotherapies for cognitive and metabolic consequences in MDD, and (2)\n      clarify the shared biological mechanisms between mood, immune and metabolism homeostasis"
        }, 
        "brief_title": "Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Inflammation", 
                "Insulin Resistance", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 16-65 years old\n\n          -  Signed informed consent by patient or legal representative\n\n          -  Hamilton Rating Scale for Depression (HDRS) scores \u2265 16\n\n          -  A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry\n\n        Exclusion Criteria:\n\n          -  Monoamine oxidase inhibitor or antidepressant treatment prior to entering the study\n\n          -  A DSM-IV diagnosis of substance abuse within the past three months\n\n          -  An organic mental disease, mental retardation or dementia\n\n          -  A serious surgical condition or physical illness\n\n          -  Patients who were pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699490", 
            "org_study_id": "NSC 101-2314-B-006 -064 -MY3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fluoxetine + Valsartan", 
                "description": "The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.", 
                "intervention_name": "Fluoxetine + Valsartan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Prozac", 
                    "Diovan"
                ]
            }, 
            {
                "arm_group_label": "Fluoxetine + Placebo", 
                "description": "The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.", 
                "intervention_name": "Fluoxetine + Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Prozac"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluoxetine", 
                "Insulin", 
                "Valsartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Major Depressive Disorder", 
            "Antidepressants", 
            "Insulin", 
            "Fluoxetine"
        ], 
        "lastchanged_date": "October 2, 2012", 
        "location": {
            "contact": {
                "email": "chenps@mail.ncku.edu.tw", 
                "last_name": "Po See Chen, M.D., Ph.D.", 
                "phone": "+886-6-2353535", 
                "phone_ext": "5213"
            }, 
            "facility": {
                "address": {
                    "city": "Tainan", 
                    "country": "Taiwan", 
                    "zip": "701"
                }, 
                "name": "Department of Psychiatry, National Cheng-Kung University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder", 
        "overall_contact": {
            "email": "chenps@mail.ncku.edu.tw", 
            "last_name": "Po See Chen, M.D., Ph.D.", 
            "phone": "+886-6-2353535", 
            "phone_ext": "5213"
        }, 
        "overall_official": {
            "affiliation": "National Cheng-Kung University Hospital", 
            "last_name": "Po See Chen, M.D., Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hamilton Depression Rating Scale (HDRS)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699490"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cheng-Kung University Hospital", 
            "investigator_full_name": "Po-See, Chen", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "fasting serum insulin", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "C-reactive Protein, and IL-6", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "National Cheng-Kung University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Science Council, Taiwan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Cheng-Kung University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}